any recurrence of symptomatic AF or asymptomatic AF and atrial flutter/tachycardia in the absence of AAD therapy during a follow-up period of 6 months 6 months [clinicaltrials_resource:4b394fbed4d6cbc7e058ec398a34698c]
Three months before starting antiarrhythmic drugs, a subcutaneous loop recorder will be implanted.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
any recurrence of symptomatic AF or asymptomatic AF and atrial flutter/tachycardia in the absence of AAD therapy during a follow-up period of 6 months 6 months [clinicaltrials_resource:4b394fbed4d6cbc7e058ec398a34698c]
Three months before starting antiarrhythmic drugs, a subcutaneous loop recorder will be implanted.
Bio2RDF identifier
4b394fbed4d6cbc7e058ec398a34698c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4b394fbed4d6cbc7e058ec398a34698c
measure [clinicaltrials_vocabulary:measure]
any recurrence of symptomatic ...... a follow-up period of 6 months
time frame [clinicaltrials_vocabulary:time-frame]
description
Three months before starting a ...... op recorder will be implanted.
identifier
clinicaltrials_resource:4b394fbed4d6cbc7e058ec398a34698c
title
any recurrence of symptomatic ...... up period of 6 months 6 months
@en
type
label
any recurrence of symptomatic ...... 94fbed4d6cbc7e058ec398a34698c]
@en